Cargando…

TB case fatality and recurrence in a private sector cohort in Mumbai, India

BACKGROUND: Half of India’s three million TB patients are treated in the largely unregulated private sector, where quality of care is often poor. Private provider interface agencies (PPIAs) seek to improve private sector quality of care, which can be measured in terms of case fatality and recurrence...

Descripción completa

Detalles Bibliográficos
Autores principales: Huddart, S., Ingawale, P., Edwin, J., Jondhale, V., Pai, M., Benedetti, A., Shah, D., Vijayan, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412104/
https://www.ncbi.nlm.nih.gov/pubmed/34802496
http://dx.doi.org/10.5588/ijtld.21.0266
_version_ 1783747392444563456
author Huddart, S.
Ingawale, P.
Edwin, J.
Jondhale, V.
Pai, M.
Benedetti, A.
Shah, D.
Vijayan, S.
author_facet Huddart, S.
Ingawale, P.
Edwin, J.
Jondhale, V.
Pai, M.
Benedetti, A.
Shah, D.
Vijayan, S.
author_sort Huddart, S.
collection PubMed
description BACKGROUND: Half of India’s three million TB patients are treated in the largely unregulated private sector, where quality of care is often poor. Private provider interface agencies (PPIAs) seek to improve private sector quality of care, which can be measured in terms of case fatality and recurrence rates. METHODS: We conducted a retrospective cohort survey of 4,000 private sector patients managed by the PATH PPIA between 2014 and 2017. We estimated treatment and post-treatment case-fatality ratios (CFRs) and recurrence rates. We used Cox proportional hazards models to identify predictors of fatality and recurrence. Patient loss to follow-up was adjusted for using selection weighting. RESULTS: The treatment CFR was 7.1% (95% CI 6.0–8.2). At 24 months post-treatment, the CFR was 2.4% (95% CI 1.7–3.0) and the recurrence rate was 1.9% (95% CI 1.3–2.5). Treatment fatality was associated with age (HR 1.02, 95% CI 1.02–1.03), clinical diagnosis (HR 0.61, 95% CI 0.45–0.84), treatment duration (HR 0.09, 95% CI 0.06–0.10) and adherence. Post-treatment fatality was associated with treatment duration (HR 0.87, 95% CI 0.79–0.91) and adherence. CONCLUSIONS: We found a moderate treatment phase CFR among PPIA-managed private sector patient with low rates of post-treatment fatality and recurrence. Routine monitoring of patient outcomes after treatment would strengthen PPIAs and inform future post TB interventions.
format Online
Article
Text
id pubmed-8412104
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher International Union Against Tuberculosis and Lung Disease
record_format MEDLINE/PubMed
spelling pubmed-84121042021-09-03 TB case fatality and recurrence in a private sector cohort in Mumbai, India Huddart, S. Ingawale, P. Edwin, J. Jondhale, V. Pai, M. Benedetti, A. Shah, D. Vijayan, S. Int J Tuberc Lung Dis Original Articles BACKGROUND: Half of India’s three million TB patients are treated in the largely unregulated private sector, where quality of care is often poor. Private provider interface agencies (PPIAs) seek to improve private sector quality of care, which can be measured in terms of case fatality and recurrence rates. METHODS: We conducted a retrospective cohort survey of 4,000 private sector patients managed by the PATH PPIA between 2014 and 2017. We estimated treatment and post-treatment case-fatality ratios (CFRs) and recurrence rates. We used Cox proportional hazards models to identify predictors of fatality and recurrence. Patient loss to follow-up was adjusted for using selection weighting. RESULTS: The treatment CFR was 7.1% (95% CI 6.0–8.2). At 24 months post-treatment, the CFR was 2.4% (95% CI 1.7–3.0) and the recurrence rate was 1.9% (95% CI 1.3–2.5). Treatment fatality was associated with age (HR 1.02, 95% CI 1.02–1.03), clinical diagnosis (HR 0.61, 95% CI 0.45–0.84), treatment duration (HR 0.09, 95% CI 0.06–0.10) and adherence. Post-treatment fatality was associated with treatment duration (HR 0.87, 95% CI 0.79–0.91) and adherence. CONCLUSIONS: We found a moderate treatment phase CFR among PPIA-managed private sector patient with low rates of post-treatment fatality and recurrence. Routine monitoring of patient outcomes after treatment would strengthen PPIAs and inform future post TB interventions. International Union Against Tuberculosis and Lung Disease 2021-09-01 2021-09-01 /pmc/articles/PMC8412104/ /pubmed/34802496 http://dx.doi.org/10.5588/ijtld.21.0266 Text en © 2021 The Union https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Original Articles
Huddart, S.
Ingawale, P.
Edwin, J.
Jondhale, V.
Pai, M.
Benedetti, A.
Shah, D.
Vijayan, S.
TB case fatality and recurrence in a private sector cohort in Mumbai, India
title TB case fatality and recurrence in a private sector cohort in Mumbai, India
title_full TB case fatality and recurrence in a private sector cohort in Mumbai, India
title_fullStr TB case fatality and recurrence in a private sector cohort in Mumbai, India
title_full_unstemmed TB case fatality and recurrence in a private sector cohort in Mumbai, India
title_short TB case fatality and recurrence in a private sector cohort in Mumbai, India
title_sort tb case fatality and recurrence in a private sector cohort in mumbai, india
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412104/
https://www.ncbi.nlm.nih.gov/pubmed/34802496
http://dx.doi.org/10.5588/ijtld.21.0266
work_keys_str_mv AT huddarts tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia
AT ingawalep tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia
AT edwinj tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia
AT jondhalev tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia
AT paim tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia
AT benedettia tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia
AT shahd tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia
AT vijayans tbcasefatalityandrecurrenceinaprivatesectorcohortinmumbaiindia